Clinical Trials Logo

Intracranial Arteriosclerosis clinical trials

View clinical trials related to Intracranial Arteriosclerosis.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04573010 Withdrawn - Ischemic Stroke Clinical Trials

Reducing Intracranial atheroSclErosis With Repatha

RISER
Start date: December 1, 2020
Phase: Phase 4
Study type: Interventional

The purpose of this study will be to understand the underlying mechanism by which PCSK9 inhibition reduces the rate of ischemic stroke seen in the pivotal studies that led to its FDA approval for ASCVD such as ischemic stroke. Those trials (FOURIER and ODYSSEY) enrolled almost 50,000 patients and showed that PCSK9 inhibition therapy is safe and effective. The investigators hypothesize that PCSK9 inhibition lowers the rate of stroke by reducing atherosclerotic plaque, which would be particularly beneficial for patients with intracranial atherosclerosis, who have the highest rate of recurrent stroke of any stroke mechanism.

NCT ID: NCT04325932 Withdrawn - Clinical trials for Intracranial Arteriosclerosis

Study of Urinary Kallikrein to Enhance Collateral Circulation in Symptomatic Intracranial Atherosclerosis

Start date: January 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether Urinary Kallikrein has an additional effect on enhancing collateral circulation in symptomatic intracranial atherosclerotic patients under clopidogrel and aspirin dual antiplatelet therapy.